Takeda, Twi must face US antitrust claims over Dexilant, judge rules
MLex Summary: Takeda Pharmaceutical and Twi Pharmaceuticals were denied dismissal of claims accusing them of engaging in an illegal reverse payment agreement to restrain competition in the US market for Dexilant...To view the full article, register now.
Already a subscriber? Click here to view full article